Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is a publicly traded Healthcare sector company. As of May 21, 2026, IRWD trades at $3.85 with a market cap of $576.15M and a P/E ratio of 5.98. IRWD moved +6.81% today. Year to date, IRWD is -14.60%; over the trailing twelve months it is +500.86%. Its 52-week range spans $0.53 to $5.78. Analyst consensus is buy with an average price target of $7.50. Rallies surfaces IRWD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ironwood Delivers $0.24 EPS in Q1, Tops Estimates After Prior-Year Loss: Ironwood Pharmaceuticals delivered first-quarter earnings of $0.24 per share, outperforming the consensus estimate of $0.07 and swinging from a $0.14 per share loss a year earlier. Revenue also exceeded consensus estimates.
| Metric | Value |
|---|---|
| Price | $3.85 |
| Market Cap | $576.15M |
| P/E Ratio | 5.98 |
| EPS | $0.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.78 |
| 52-Week Low | $0.53 |
| Volume | 5.04K |
| Avg Volume | 0 |
| Revenue (TTM) | $361.51M |
| Net Income | $102.18M |
| Gross Margin | 0.00% |
3 analysts cover IRWD: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.50.